Alexion Pharmaceuticals, Inc. (ALXN)

182.50
Prev Close 182.50
Day Low/High 0.00 / 0.00
52 Wk Low/High 99.91 / 187.45
Exchange
Div & Yield N.A. (N.A)
Dodging the Snakes, Dissonant Dance With China, Dipping Into the Chip Bowl

Dodging the Snakes, Dissonant Dance With China, Dipping Into the Chip Bowl

Those rattles you hear on the COVID, Fed and political fronts are reasons to tread carefully in the markets.

Biotech Isn't Seeing Much Merger Activity, but Here's a Stock to Like

Biotech Isn't Seeing Much Merger Activity, but Here's a Stock to Like

Dynavax Technologies has inked a supply deal related to a Covid-19 vaccine that could greatly increase its revenue stream.

Jim Cramer: Market Sees Successful Vaccine Rollout as a Long Shot

Jim Cramer: Market Sees Successful Vaccine Rollout as a Long Shot

Ending the pandemic swiftly appears unlikely, so here's how to look at key stocks and sectors right now -- especially as concerns of new lockdowns grow.

How I'm Playing Astra-Zeneca on Vaccine and Acquisition News

How I'm Playing Astra-Zeneca on Vaccine and Acquisition News

I am staying away from this name for now, despite the Alexion acquisition and vaccine promise.

2 Potential Acquisition Targets as Biotech Deal Activity Picks Up

2 Potential Acquisition Targets as Biotech Deal Activity Picks Up

BioXcel Therapeutics and Avadel Pharmaceuticals would make good additions to the portfolios of larger drug companies.

Alexion Is Reaching New Heights

Alexion Is Reaching New Heights

Shares of this biotech company look like a good opportunity.

I Liked These 4 Stocks Before Earnings, Now I Like Them Even More

I Liked These 4 Stocks Before Earnings, Now I Like Them Even More

Here's an update of our investment themes on these companies.

On the Lookout for Revenue Rebounds Among Covid-Dinged Biotechs

On the Lookout for Revenue Rebounds Among Covid-Dinged Biotechs

The early stages of the pandemic hurt sales at many biotech companies, but there are signs that revenue streams are picking back up.

Alexion Pharmaceuticals Just Made an Upside Breakout: Here's What to Do

Alexion Pharmaceuticals Just Made an Upside Breakout: Here's What to Do

Let's check out the charts of this drug maker that raised its full-year 2020 revenue guidance.

3 Covid-Proof Plays Not Named Amazon or Apple

3 Covid-Proof Plays Not Named Amazon or Apple

Tutor Perini, Beazer Homes and Alexion Pharmaceuticals all turned in solid results in the face of the pandemic.

Strength in Alexion Pharmaceuticals May Be Temporary

Strength in Alexion Pharmaceuticals May Be Temporary

Be cautious about ALXN in the short-run.

Alexion Rated New Neutral at Cantor

Keeping Sane, the Profitable Way: How I'm Playing This Market

Keeping Sane, the Profitable Way: How I'm Playing This Market

I continue to shuttle new money into the market on declines using buy-write option strategies.

4 Biotech Stocks I'm Targeting Now

4 Biotech Stocks I'm Targeting Now

I've stayed primarily to those names that have plenty of cash on the balance sheet and should be just fine once saner heads prevail.

2 Healthcare Stocks That Look Like Bargains Relative to Their Growth Prospects

2 Healthcare Stocks That Look Like Bargains Relative to Their Growth Prospects

Alexion Pharmaceuticals and Lantheus Holdings are interesting names at current trading levels.

Alexion Pharmaceuticals Does Not Look Boston Strong

Alexion Pharmaceuticals Does Not Look Boston Strong

Charts of the Boston-based biotech to do not provide a compelling case to buy the stock.

Big Biotech Receives Some Needed Shots in the Arm

Big Biotech Receives Some Needed Shots in the Arm

Biogen, Novartis and Bristol-Myers Squibb are among the drugmakers that gave investors reasons for cheer on Tuesday.

6 Top Biopharmaceutical Stock Picks You Should Know About

6 Top Biopharmaceutical Stock Picks You Should Know About

The aging population is creating a massive tailwind for companies that provide cutting-edge health care.

Here Are Several Promising Rare Disease Stocks

Here Are Several Promising Rare Disease Stocks

These small biotech concerns are undervalued.

I'm Unapologetically Overweight in These 2 Sectors

I'm Unapologetically Overweight in These 2 Sectors

The two are homebuilding and biotech, and there are stocks within those sectors where I've parked my money.

3 Biotech Plays That Would Work as Covered Calls

3 Biotech Plays That Would Work as Covered Calls

The SPDR S&P Biotech ETF, Alexion Pharmaceuticals and BioMarin Pharmaceuticals set up nicely for this options strategy.

Alexion Rated New Outperform at BMO

A Sagging Drugmaker and Lagging Pet Health Name Both Worth Looks

A Sagging Drugmaker and Lagging Pet Health Name Both Worth Looks

Alexion Pharmaceuticals and Elanco Animal Health have seen their shares go to the dogs of late, but still offer reasons for portfolio consideration.

The Market Has Fury for a Suitor Scorned

Otezla Price Under Microscope -- but Look Closely and It Checks Out

Otezla Price Under Microscope -- but Look Closely and It Checks Out

Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.

Amgen Adds Celgene's Otezla to Bolster Pipeline at Pricey Valuation

Amgen Adds Celgene's Otezla to Bolster Pipeline at Pricey Valuation

Amgen is finally making an expected splash out of its cash pile, but questions are abounding about the cost paid for Celgene's Otezla.

A Pair of Rare Disease Biotech Concerns Worth a Good Look

A Pair of Rare Disease Biotech Concerns Worth a Good Look

Alexion Pharmaceuticals is a solid company that is the subject of acquisition rumors and Amicus Therapeutics has a key drug off to a strong start.

5 Favorites for Biotech Stock Buyers

5 Favorites for Biotech Stock Buyers

For those with a long-term horizon, here are some top picks.

A Handful of Small Biotechs That Make for Merger Chatter

A Handful of Small Biotechs That Make for Merger Chatter

The names include a veterinary drug concern plus companies with successful drugs on the market.